ADC Therapeutics SA reports results for the quarter ended in December - Earnings Summary

ADC Therapeutics SA

13/03/2024 13:31

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of $1.03​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -30 cents.  The mean expectation of five analysts for the
quarter was for a loss of 50 cents per share. Wall Street
expected results to range from -67 cents to -17 cents per share.
    * Revenue fell 75.9% to $16.79 million from a year ago;
analysts
expected $15.33 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss of
$1.03​.
    * The company reported a quarterly loss of $85.03 million.
    * ADC Therapeutics SA shares had risen by 168.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 10.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ADC Therapeutics
SA is $8.50 
This summary was machine generated from LSEG data March 13 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.50          -1.03          Missed
 Sep. 30 2023      -0.63          -0.58          Beat
 Jun. 30 2023      -0.46          -0.58          Missed
 Mar. 31 2023      -0.67          -0.74          Missed